疫苗创新优先策略:三国利益相关方咨询的发现
作为疫苗创新优先策略(VIPS)的一部分,2018年9月至2020年2月期间开展了三次免疫利益相关方咨询,旨在确保国家需求驱动疫苗产品创新的优先排序。咨询包括在线调查和深度访谈,覆盖多国免疫规划相关人员,识别了免疫实施障碍、期望的疫苗属性及优先创新产品。
要点
- 固定场所接种中,因不愿开启多剂次疫苗瓶导致的接种机会错过是最常见障碍。
- 社区和宣传活动场景中,地理障碍导致的免疫服务可及性受限最常见。
- 微针贴片、双腔给药装置和热稳定/控温链液体疫苗被列为最具影响力的创新。
核心结论
- 国家免疫规划利益相关方认为多剂次瓶、热稳定性不足和地理可及性是主要障碍,微针贴片等创新可最大程度应对当前挑战。
研究设计与样本
- 2018年9月至2020年2月开展三次免疫利益相关方咨询:两次在线调查和一次深度访谈,对象为具有免疫规划经验的人员。
- 第一次调查纳入61个国家442名参与者,占正确完成至少一部分在线调查的496名应答者的89%。
- 第二次在线调查由54个国家220名应答者完成。
- 深度访谈纳入6个国家84名应答者。
主要发现
- 固定场所接种中,因不愿开启多剂次疫苗瓶导致的接种机会错过是最常被选择的障碍。
- 社区外展和宣传活动场景中,地理障碍导致的免疫服务可及性受限最常被选择。
- 固定场所接种最常被选择的期望疫苗属性为含防腐剂多剂次或单剂次 presentations。
- 外展和宣传场景最常被选择的期望疫苗属性为改善的热稳定性。
- 示例疫苗中,热或冷冻暴露导致的疫苗无效或浪费以及多剂次瓶导致的接种机会错过被认定为最大的疫苗特异性挑战。
关键数值与推荐
- 深度访谈将微针贴片、双腔给药装置和热稳定/控温链合格液体疫苗列为最能帮助应对当前免疫规划挑战的三项创新。
临床怎么用
- 上述发现为VIPS优先排序提供依据,并可更广泛地用于设计免疫干预措施以更好满足国家需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As part of the Vaccine Innovation Prioritisation Strategy (VIPS), three immunization-stakeholder consultations were conducted between September 2018 and February 2020 to ensure that countries' needs drove the prioritization of vaccine product innovations. All consultations targeted respondents with immunization program experience. They included: (1) an online survey to identify immunization implementation barriers and desired vaccine attributes in three use settings, (2) an online survey to identify and evaluate the most important immunization challenges for ten exemplar vaccines, and (3) in-depth interviews to better understand the perceived programmatic benefits and challenges that could be addressed by nine innovations and to rank the innovations that could best address current challenges. The first consultation included responses from 442 participants in 61 countries, representing 89% of the 496 respondents who correctly completed at least one section of the online survey. For facility-based settings, missed opportunities for vaccination due to reluctance to open multidose vaccine vials was the barrier most frequently selected by respondents. In community-based (outreach) and campaign settings, limited access to immunization services due to geographic barriers was most frequently selected. Multidose presentations with preservative or single-dose presentations were most frequently selected as desired vaccine attributes for facility-based settings while improved thermostability was most frequently selected for outreach and campaign settings. The second online survey was completed by 220 respondents in 54 countries. For the exemplar vaccines, vaccine ineffectiveness or wastage due to heat or freeze exposure and missed opportunities due to multidose vial presentations were identified as the greatest vaccine-specific challenges. In-depth interviews with 84 respondents in six countries ranked microarray patches, dual-chamber delivery devices, and heat-stable/controlled temperature chain qualified liquid vaccines as the three innovations that could have the greatest impact in helping address current immunization program challenges. These findings informed the VIPS prioritization and provided broader application to designing immunization interventions to better meet country needs.
引用
- Mvundura M, Frivold C, Janik Osborne A, et al. Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations. Vaccine. 2021. PMID: 34412922. doi:10.1016/j.vaccine.2021.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。